EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLP-1 receptor agonists in osteoarthritis and psoriatic disease: the missing link between obesity and inflammation?

Andreas Angelopoulos, George E Fragoulis, Charalampos Papagoras, Dimitrios Daoussis

Rheumatology International · 2026

DOI: 10.1007/s00296-026-06258-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Rheumatology International, 2026. Verfasst von Andreas Angelopoulos und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Patras Medical School, Patras, Greece. andaggel@hotmail.com. Hauptthemen laut MEDLINE: Osteoarthritis, Obesity, Glucagon-Like Peptide-1 Receptor Agonists, Psoriasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Patras.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Excessive body weight stands out as a major, well-documented risk factor for rheumatic and musculoskeletal diseases (RMDs). Indeed, high body mass index (BMI) affects disease severity, treatment response, and long-term outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were first developed for type 2 diabetes and obesity, but there is growing evidence that they may also have anti-inflammatory and immunomodulatory properties [1–3]. This narrative review examines the available evidence on the role of GLP-1 RAs in two conditions that are strongly associated with metabolic and mechanical factors but sit on almost opposite ends of the inflammatory spectrum: osteoarthritis (OA), a predominantly mechanically driven disease, and psoriatic disease (PsD), an immune-mediated inflammatory disease. A comprehensive narrative review of the literature was conducted to evaluate preclinical and clinical evidence regarding the effects of GLP-1 signaling in both OA and PsD. Preclinical data suggest that GLP-1 signaling may protect cartilage, reduce inflammation, and alleviate pain in OA. Early clinical evidence is encouraging, showing reductions in both joint pain and body weight. In PsD, obesity and psoriatic inflammation share several common pathways, particularly through the IL-17/IL-23 axis, which provides a theoretical biological rationale for GLP-1 RAs use in this setting, although direct clinical evidence remains limited and largely derived from studies in obese patients. Dedicated randomized controlled trials are necessary to clarify the direct immunomodulatory mechanisms involved and to define the precise position of GLP-1 RAs in rheumatological practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoarthritisObesityGlucagon-Like Peptide-1 Receptor AgonistsPsoriasisAnti-Inflammatory AgentsHumansAnimalsInflammationGlucagon-Like Peptide-1 ReceptorSignal Transduction

Stichwörter der Autor:innen

ArthritisGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like peptideObesityOsteoarthritisPsoriasisPsoriatic

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsAnti-Inflammatory AgentsGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • University of Patras Medical School, Patras, Greece. andaggel@hotmail.com.
  • First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
  • Department of Rheumatology, Patras University Hospital, University of Patras Medical School, Patras, Greece.

Förderung

  • University of Patras

Zitieren

APA

Angelopoulos, A., Fragoulis, G. E., Papagoras, C., & Daoussis, D. (2026). GLP-1 receptor agonists in osteoarthritis and psoriatic disease: the missing link between obesity and inflammation?. Rheumatology International. https://doi.org/10.1007/s00296-026-06258-2

Vancouver

Angelopoulos A, Fragoulis GE, Papagoras C, Daoussis D. GLP-1 receptor agonists in osteoarthritis and psoriatic disease: the missing link between obesity and inflammation?. Rheumatology International. 2026. doi:10.1007/s00296-026-06258-2

BibTeX
@article{Angelopoulos2026,
  author = {Angelopoulos, Andreas and Fragoulis, George E and Papagoras, Charalampos and Daoussis, Dimitrios},
  title = {GLP-1 receptor agonists in osteoarthritis and psoriatic disease: the missing link between obesity and inflammation?},
  journal = {Rheumatology International},
  year = {2026},
  doi = {10.1007/s00296-026-06258-2}
}
Kostenlos starten →